logo

For the Inventor, By the Inventor

Lexington, MA, United States of America

Aldeyra Therapeutics, Inc.

USPTO Granted Patents = 40



Trademarks = 1

Forward Citations = 572

Loading Chart...
Loading Chart...

28 inventors (with patents filed for the assignee):

goldMedal Todd Brady (17 out of 17 patents)

silverMedal Scott Young (15 out of 15 patents)

bronzeMedal William Alvin Kinney (15 out of 65 patents)

4.  Stephen Gitu Machatha (13 out of 13 patents)

5.  Thomas A Jordan (11 out of 14 patents)

6.  John Clifford Chabala (11 out of 29 patents)

7.  Susan Macdonald (10 out of 10 patents)

8.  Kenneth Jason Mandell (8 out of 22 patents)

9.  John E Dowling (7 out of 10 patents)

10.  Dean Eliott (4 out of 12 patents)

11.  Tomasz Stryjewski (4 out of 4 patents)

12.  David J Clark (3 out of 73 patents)

13.  Hannah Ruth McLachlan (3 out of 3 patents)

14.  Gregor Sneddon (3 out of 3 patents)

15.  Jonathan James Loughrey (3 out of 13 patents)


Core Competencies:
Ophthalmic Formulations
Methotrexate
Toxic Aldehyde
Deuterated Compounds
Macular Degeneration
Retinal Disease
Inflammatory Disorders
Dry Eye Disease
Polymorphic Compounds
Cyclodextrins
Combination Treatment
Aldehyde Scavenger

40 patents:

1. 12616699 - Ophthalmic formulations of methotrexate (2026-05-05),
2. 12240816 - Deuterated compounds and uses thereof (2025-03-04),
3. 12128013 - Toxic aldehyde related diseases and treatment (2024-10-29),
4. 12098132 - Process for preparation of aldehyde scavenger and intermediates (2024-09-24),
5. 12097188 - Compositions and methods for the treatment of macular degeneration (2024-09-24),
6. 12064516 - Pharmaceutical formulations and uses thereof (2024-08-20),
7. 12029735 - Polymorphic compounds and uses thereof (2024-07-09),
8. 12006298 - Polymorphic compounds and uses thereof (2024-06-11),
9. 12005061 - Ophthalmic formulations of methotrexate (2024-06-11),
10. 12005060 - Ophthalmic formulations of methotrexate (2024-06-11),
11. 11911385 - Methotrexate treatment methods (2024-02-27),
12. 11845722 - Deuterated compounds and uses thereof (2023-12-19),
13. 11786518 - Ophthalmic formulations and uses thereof (2023-10-17),
14. 11771664 - Toxic aldehyde related diseases and treatment (2023-10-03),
15. 11724987 - Compositions and methods of treating retinal disease (2023-08-15),
Company Overview
Aldeyra Therapeutics, Inc. is a biotechnology company based in Lexington, MA, focused on developing innovative therapies for immune-mediated and retinal diseases. The company specializes in the discovery and advancement of novel treatments that target underlying disease mechanisms, particularly in areas such as dry eye disease and other ocular conditions. Aldeyra's research leverages its expertise in pharmacology and biochemistry to create solutions aimed at improving patient outcomes and addressing unmet medical needs.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Aldeyra Therapeutics, Inc. USPTO Patent Assignee Logo
40 Patents

#23 in Lexington, MA

#496 in Massachusetts

#8,635 in US

#17,087 in the World

Lexington, MA (US)
Lexington, MA, United States of America

Aldeyra Therapeutics, Inc.

Forward Citations = 572

28 inventors:

goldMedal Todd Brady (17 out of 17 patents)

silverMedal Scott Young (15 out of 15 patents)

bronzeMedal William Alvin Kinney (15 out of 65 patents)

4.  Stephen Gitu Machatha (13 out of 13 patents)

5.  Thomas A Jordan (11 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aldeyra Therapeutics, Inc.. Retrieved from https://idiyas.com/company/aldeyra-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…